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The efficacy and safety of recombinant tissue plasminogen 
activator (rt-PA) administered on a dosing per weight basis 
was evaluated in a randomized, placebo-controlled, double- 
blind trial in 115 patients with acute myocardial infarction. 
The principal outcomes were global and regional left ven- 
tricular function in the distribution of the qualifying myo- 
cardial infarction, determined 9 days after the onset of 
symptoms. 
Global and regional ejection fraction values were signif- 
icantly better for patients treated with r&PA than for 
placebo-treated patients (the differences were 5.8 f 2.7% 
units [p = 0.0171 and 7.1 f 3.1% units [p = 0.0121, 
respectively). This benefit was also evident from visual 
assessment of left ventricular segmental wall motion. After 
adjustment for differences in important prognostic varia- 
bles at baseline, the estimates of treatment effect were 4.0 2 
2.4% units (p = 0.048) for global and 4.3 f 2.6% units (p 
= 0.047) for regional ejection fraction. Early patency of the 
infarct-related vessel was demonstrable in 7 (29%) of 24 
placebo-treated patients and 18 (78%) of 23 rt-PA-treated 
patients, whereas 15 (56%) of 27 patients in the placebo 
group and 23 (72%) of 32 in the r&PA group had a patent 
infarct-related vessel at hospital day 9. 
There was no significant difference in irreversible or 
reversible defect size as assessed by thallium scintigraphy 
on day 7. There was no difference in maximal peak creatine 
kinase (CK) MB isoenzyme or area under the MB CK 
time-activity curve between the two groups; however, the 
time from symptom onset to peak MB CK was 12.9 f 0.6 
h in patients treated with rt-PA and 17.9 + 0.6 h in those 
treated with placebo (p < 0.001). Twenty patients under- 
went coronary angioplasty or cardiac surgery in the hospi- 
tal; 5 of these had received placebo and 15 had received 
rt-PA (p = 0.014); 12 of these procedures were performed 
at or after day 9. No instances of cerebral hemorrhage and 
no significant adverse effects were seen in this study. This 
study demonstrates the benefit of rt-PA on global and 
regional left ventricular function in the area of qualifying 
myocardial infarction. 
(J Am Co11 Cardioll989;13:1469-76) 
Coronary thrombosis has a primary role in the pathogenesis 
of acute myocardial infarction and both the short- and the 
long-term prognosis of this disorder are ultimately depen- 
dent on the extent of resulting myocardial damage (1,2). 
Recent data (3,4) indicate that coronary thrombolysis has the 
potential to improve left ventricular function and to reduce 
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subsequent mortality. Tissue plasminogen activator, a natu- 
rally occurring human protein, plays a pivotal role in the in 
vivo mediation of thrombolysis and is relatively fibrin spe- 
cific. When administered intravenously, recombinant tissue 
plasminogen activator (rt-PA) provides effective coronary 
thrombolysis without the induction of a profound systemic 
lytic state and, as such, is thought to have particular promise 
in the management of acute myocardial infarction. 
The purpose of this study was to examine the efficacy and 
safety of double-chain rt-PA (Burroughs Wellcome Co.) in 
the management of acute myocardial infarction. Previous 
data (5) suggested a dose-dependent thrombolytic efficacy of 
this rt-PA preparation, but there are no studies evaluating its 
effect on the left ventricular function of patients. Because 
preliminary studies (5,6) indicated that a risk of hemorrhage 
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was related to total dosage of rt-PA, the dose of rt-PA 
administered in this study was adjusted to the body weight of 
recipients. Because it has been suggested that reperfusion 
therapy with t-t-PA promotes further instability and increases 
the risk of recurrent myocardial ischemia, it has been 
reasoned that access to early mechanical revascularization is 
required. Given the substantial logistic and economic impli- 
cations of this approach, in this study we restricted mechan- 
ical revascularization to individuals who developed pre- 
defined ischemic end points. This was done to assess the 
independent influence of pharmacologically induced coro- 
nary reperfusion on the principal outcomes of our study, 
regional and global left ventricular function on the 9th 
hospital day. 
Methods 
This was a randomized, placebo-controlled, double-blind 
trial. The principal outcomes were global and regional left 
ventricular function in the distribution of the qualifying 
myocardial infarction determined 9 days after the onset of 
symptoms. The protocol and consent form were approved 
by the Human Subjects Review Committee, University of 
Toronto and the institutional review boards of the partici- 
pating hospitals. 
Study patients. Patients aged 20 to 75 years with typical 
ischemic chest pain lasting ~30 min, ST segment elevation in 
the electrocardiogram (ECG) ~0.1 mV in two inferior leads 
or leads I and aVL or 20.15 mV in at least two anterior 
precordial leads were considered for admission to the study. 
Patients were excluded if they presented >3.75 h after the 
onset of chest pain or had cardiogenic shock, left bundle 
branch block, prior aortocoronary bypass surgery or recent 
(< 1 month) percutaneous transluminal coronary angio- 
plasty, obvious contraindications to thrombolytic therapy or 
inability to provide informed consent. Patients were re- 
cruited from 10 collaborating hospitals in Toronto and rec- 
ords were kept of those who met inclusion criteria but were 
not randomized. Randomization was balanced within each 
hospital according to blocks of four. Of these 10 hospitals, 3 
were designated as core hospitals on the basis of their 
capacity to perform coronary angiography. Patients initially 
admitted to any of the seven non-core hospitals were trans- 
ferred by random assignment to one of the three core 
hospitals on the 4th hospital day. All investigations after day 
4, including ventricular function studies, were performed in 
one of these three core institutions. 
Treatment protocol. Study treatment consisted of dou- 
ble-chain recombinant tissue plasminogen activator @-PA) 
(Burroughs Wellcome Co.) or matching placebo. The first 39 
patients received the study drug at 0.4 MU/kg per h intrave- 
nously for h 1,O. 14 MU/kg per h for h 2 and 0.03 MU/kg per 
h for the subsequent 8 h. The final 79 patients received 0.4 
MU/kg per h for h 1,0.08 MU/kg per h for h 2, and 0.03 MU/ 
kg per h for the subsequent 4 h. Ten percent of the h 1 dose 
was given as a bolus injection initially. All patients received 
heparin, concomitant with the study drug, commencing with 
a bolus injection of 4,000 IU followed by an infusion of 1,000 
IU/h. Heparin administration was continued for 96 h and 
monitored by periodic partial thromboplastin times with the 
objective of maintaining the partial thromboplastin time 
between 1.5 and 2 times the control value. In all patients, 325 
mglday of enteric-coated aspirin was given orally before 
cessation of heparin therapy. All patients received prophy- 
lactic lidocaine therapy for the first 24 h. 
Assessment of left ventricular function. Left ventricular 
function was assessed with radionuclide ventriculography 
3.8 ? 0.8 h after initiation of treatment and again on day 9. 
Studies were acquired in the anterior, 45” left anterior 
oblique and 70” left anterior oblique views using multigated 
acquisition of 32 frames/cardiac cycle after in vitro labeling 
of red blood cells with 30 mCi of technetium-99m. On day 9, 
the 45” left anterior oblique view study was repeated 2 min 
after the administration of 0.6 mg of sublingual nitroglycerin. 
All day 1 radionuclide studies were transferred from the 10 
participating hospitals to the core nuclear laboratory as were 
all day 9 studies performed at the 3 core hospitals. One 
technologist who did not know the clinical data analyzed all 
day 1 and day 9 studies on a single computer system. 
Global left ventricular ejection fraction was calculated 
with use of a semiautomated method for definition of end- 
diastolic and end-systolic regions with calculation of back- 
ground from a left paraventricular region of interest. Re- 
gional ejection fractions in the 45” left anterior oblique view 
were calculated for one inferoapical, two septal and two 
posterolateral segments, each segment encompassing 60” of 
the circumference of the ventricle. Assignment of segments 
for regional calculations was keyed to the qualifying electro- 
cardiogram (ECG). For anterior infarction, the inferoapical 
and the two septal segments were averaged, and for inferior 
infarction the inferoapical and the two posterolateral seg- 
ments were averaged to give the regional ejection fraction in 
the area of infarction. 
Segmental wall motion was assessed in five segments in 
the anterior view, in five in the 45” left anterior oblique view 
and in two inferior segments in the 70” left anterior oblique 
view and were scored 0 to 4 according to whether the 
segment was normal [0], mildly hypokinetic [l], severely 
hypokinetic [2], akinetic [3] or dyskinetic [4]. Wall motion 
was assessed by two experienced observers unaware of 
treatment assignment; differences were mediated by consen- 
sus. All readings were conducted at the core nuclear labo- 
ratory. A wall motion score was calculated as the sum of the 
segmental score divided by the total number of assessed 
segments for global and regional measurements, respec- 
tively. 
Enzymatic assessment of myocardial infarction was ob- 
tained by utilizing serum levels of creatine kinase (CK) and 
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MB CK in international units per liter determined at 4 h 
intervals for the first 36 h. Thereafter, CK activity in 
international units per liter was determined at 12 h intervals 
throughout the hospital course. Reinfarction was defined as 
an increase of ~50% in MB CK activity over a previously 
established basal level. Creatine kinase activity was deter- 
mined with the use of Boehringer Mannheim activated 
automated analysis with N-acetylcysteine reagents, and MB 
CK activity with the use of Isoimmune-CK (Roche). 
Cardiac catheterization protocol. Cardiac catheterization 
was performed according to a predetermined protocol. For 
the 47 patients who were initially admitted to the three core 
institutions with facilities for cardiac catheterization, pa- 
tency of the infarct-related coronary artery was determined 
18 i 6 h after administration of the study drug. All coronary 
angiograms were independently reviewed without knowl- 
edge of clinical or other data at a core angiographic site and 
infarct-related vessel patency was classified according to the 
criteria of the Thrombolysis in Myocardial Infarction (TIMI) 
investigators (7). Patency of the infarct-related vessel was 
defined as TIM1 perfusion grade 2 or 3, and patients with a 
patent vessel were restudied on day 9 to document the 
reocclusion rates in this subset. The 59 patients initially 
admitted to a hospital without facilities for catheterization 
were transferred by random assignment to one of the three 
core hospitals on day 4 and underwent coronary angiography 
on day 9 to provide an unbiased estimate of late coronary 
patency. Nine additional randomized patients (five assigned 
to placebo and four assigned to rt-PA) did not undergo 
coronary angiography because of patient refusal (three 
cases), death (two cases), urgent revascularization (three 
cases) and an administrative problem (one case). 
Exercise thallium scintigraphy. All patients underwent 
symptom-limited exercise thallium scintigraphy on day 8 
according to the Bruce protocol. After intravenous injection 
of 3.0 mCi of thallium-201 during peak exercise, the patient 
exercised for 1 additional min and was then placed in the 
supine position. Five minutes after exercise. an anterior 
planar image was obtained followed by continuous acquisi- 
tion of images beginning in the 45” right anterior oblique 
projection and moving clockwise around the heart to + 135” 
left anterior oblique; these images were stored on a mini- 
computer in a 64 x 64 matrix at 3” intervals. Thallium images 
were obtained in the three core hospitals that performed 
cardiac catheterization and data were transferred to the core 
nuclear laboratory. Thallium tomograms were reconstructed 
and a polar coordinate map of activity was obtained and 
displayed in a “bull’s-eye” format; 4 h delayed images were 
similarly acquired and processed. The stress and 4 h bull’s- 
eye displays were compared with limits defined from 17 
normal subjects; activity 2.5 SD below these limits was 
considered abnormal. Stress defects were quantitatively 
determined and localized to either anterior or inferior vas- 
cular territories and their size was expressed as the percent 
of the total bull’s-eye display. The area of the initial defect 
that was reversible or nonreversible was calculated by 
comparison of the stress and 4 h studies. 
Post-treatment protocol. Patients were systematically 
monitored for clinical and ECG evidence of recurrent isch- 
emia. Particular attention was given to the avoidance of 
associated interventions that could affect study outcome. 
Therefore, coronary angioplasty and aortocoronary bypass 
surgery within the first 10 days were confined to those 
patients experiencing any of the following: 1) two or more 
episodes of recurrent ischemic chest pain during a 48 h 
period despite maximal medical therapy; 2) ischemic chest 
pain with >2 mm ST segment shift; or 3) development of 
hemodynamic instability. Revascularization at and after day 
10 was performed at the discretion of the attending cardiol- 
ogist, who had access to exercise scintigraphic and angio- 
graphic data. There was no difference between the anti- 
ischemic and other medical therapy of placebo- and rt-PA- 
treated groups at day 5 or at hospital discharge. 
Clinical assessment of cardiac functional status was 
performed on admission and daily throughout the hospital 
course. Clinical follow-up study was undertaken after hos- 
pital discharge to assess mortality as well as morbidity, 
defined as recurrent ischemic events and need for revascu- 
larization. up to 90 days after randomization. 
Statistical analysis. The demographic and clinical base- 
line characteristics of the two treatment groups are summa- 
rized in terms of means and standard errors (‘-SE) for 
continuous data and relative frequencies (ie. percentages) 
for categorical features. Similar summaries were used for 
efficacy outcomes with the addition of formal significance 
tests. Student’s t test was used for comparing treatment 
means and Fisher exact test for proportions. In general, 
one-tailed tests were performed where clear. predetermined 
directional hypotheses existed. Provision was made before 
unblinding for comparison of treatments with the use of 
unadjusted and adjusted analyses. The adjusted analyses 
used a regression approach, i.e., analysis of covariance, 
which both corrects the observed treatment difference for 
any imbalances and baseline factors that influence outcome 
and also improves the sensitivity of the comparison by 
eliminating variation due to the baseline characteristic. We 
adjusted for a predetermined set of baseline covariants given 
in Table 1. 
7’hr study plan was to randomize 150 patients per group 
on the basis of anticipated beneficial effect of rt-PA on global 
and regional ejection fraction. The study was terminated 
sooner than planned when rt-PA became generally available 
and the steering committee believed it was no longer ethical 
to randomize patients to receive placebo. 
Study organization. The data coordination center for this 
trial was the Department of Clinical Epidemiology and 
Biostatistics at McMaster University (Hamilton, Ontario. 
Canada). The records of all patients who were randomized 
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(n = 56) 
rt-PA 
Group 





History of prior MI 
History of hypertension 
Time to treatment (h) 
Infarct location 
(anterior) 
Killip class I 
51.1 ? 1.3 56.5 ? 1.3 0.519 
41(84%) 50 (85%) 0.904 
2 (4%) 8 (14%) 0.0% 
21 (37%) 19 (32%) 0.5Sl 
3.0 f 0.1 3.0 + 0.1 0.792 
21(48%) 20 (34%) 0.118 
47 (84%) 49 (83%) 0.705 
Age and time to treatment measurements are expressed as mean values 
t SE. MI = myocardial infarction; rt-PA = recombinant tissue-type plasmin- 
ogen activator. 
were assessed by a central adjudications committee with 
respect to admission and exclusion criteria, departures from 
protocol, and serious adverse effects. An external safety 
monitoring committee, consisting of individuals independent 
of the trial, was provided efficacy and safety data at 3 month 
intervals to monitor the progress of this study and terminate 
study entry if the results warranted such action. The chair- 
man of the safety monitoring committee was the only indi- 
vidual with knowledge of individual treatment allocations. 
Results 
Patient assignment to treatment groups. Between June 1 
and December 23, 1987, 600 patients met the inclusion 
criteria; 412 of these were excluded because of late presen- 
tation (>3.75 h after the onset of chest pain) (51.4%), age 
175 years (24.5%), shock (3.4%), contraindications to 
thrombolytic therapy (4.3%) and other reasons (16.5%). Of 
the 188 patients eligible for the study, 70 were not random- 
ized for administrative reasons or because consent was not 
obtained from the patient or the attending physician. Of the 
118 patients who were randomized, 3 were subsequently 
ruled ineligible because they did not have myocardial infarc- 
tion (1 patient with pericarditis, 1 with a chronic ventricular 
aneurysm and 1 with fixed repolarization abnormalities and 
left ventricular hypertrophy). There were no differences in 
the baseline characteristics between the 70 patients who 
were eligible and not randomized and the study group. Of the 
remaining 115 patients, 56 were assigned to receive placebo 
and 59 to receive rt-PA. 
Baseline characteristics (Table 1). Whereas randomiza- 
tion produced reasonably well balanced treatment groups, a 
history of prior infarction and infarct location were less well 
matched. Adjustment for potentially important influences of 
baseline variables on the assessment of treatment effect was 
accomplished by analysis of covariance with use of the 
predefined baseline characteristics outlined in Table 1. 
Radionuclide ventriculography (Table 2). Global and re- 
Table 2. Global and Regional Radionuclide Ventriculography in 







Global ejection fraction (%) 
Early 45.4 + 1.9 49.1 k 1.6 
(n = 52) (n = 54) 
Late 47.8 r 2.2 53.6 r 1.6 
(n = 50) (n = 54) 
Regional ejection fraction (%) 
Early 32.2 * 2.2 33.9 k 1.9 
(n = 52) (n = 54) 
Late 36.0 + 2.4 43.0 ? 2.0 
(n = 50) (n = 54) 
Global visual score 
Early 1.28 2 0.10 1.04 + 0.08 
(n = 52) (n = 55) 
Late 1.13 + 0.11 0.76 t 0.07 
(n = 50) (n = 55) 
Regional visual score 
Early 1.81 f 0.14 1.53 + 0.11 
(n = 52) (n = 55) 
Late 1.61 r 0.14 1.15 + 0.10 
(n = 50) (n = 55) 
t5.8 k 2.7 
(p = 0.017) 
t7.1 t 3.1 
(p = 0.012) 
-0.37 + 0.13 
(p = 0.002) 
-0.46 + 0.17 
(p = 0.003) 
Measurements are mean values f SE. Early = 3.8 k 0.8 h; Late = 
hospital day 9. p values compare late results in the two treatment groups. 
r&PA = recombinant tissue-type plasminogen activator. 
gional ejection fraction were significantly better at day 9 for 
patients treated with rt-PA than for those treated with 
placebo (the differences from baseline were 5.8 ? 2.7% units 
(p = 0.017) and 7.0 + 3.1% units (p = 0.012, respectively). 
This benefit was also evident from the visual assessments of 
left ventricular global and regional wall motion. After adjust- 
ment for baseline differences, the treatment effects were 
4.0 2 2.4% units (p = 0.048) and 4.3 + 2.6% units (p = 0.047) 
for global and regional ejection fraction, respectively. Simi- 
larly, the adjusted treatment effect was -0.27 ? 0.12 (p = 
0.01) and -0.32 ? 0.16 (p = 0.02) for global and regional 
visual score, respectively. 
After sublingual nitroglycerin, the global ejection fraction 
improved by 2.1 ? 0.6% units for placebo and 2.4 -t 0.6% 
units for rt-PA, whereas regional ejection fraction improved 
by 2.8 + 0.6% units for placebo and 3.7 + 0.8% units for 
rt-PA. The effects of rt-PA on global and regional left 
ventricular function at day 9 and the incremental change 
achieved by nitroglycerin are shown in Figure 1. When the 
five patients (three assigned to placebo and two to rt-PA) 
who underwent coronary angioplasty or cardiac surgery 
before day 9 were excluded, the significant differences in 
favor of rt-PA persisted. It is important to emphasize that 
there was also no difference in the treatment effect when 
analysis was conducted according to the two different rt-PA 
maintenance regimens. 
Coronary artery patency. Early patency of the infarct- 
related coronary artery, defined as TIMI perfusion grade 2 or 
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Global Regional 
Figure 1. Results of radionuclide angiography performed on day 9. 
At rest, both global and regional ejection fractions (open bars) were 
significantly greater for patients treated with recombinant tissue- 
type plasminogen activator (rt-PA) than for patients treated with 
placebo (p = 0.017 and p = 0.012, respectively). The improvement 
in global and regional ejection fractions after administration of 
sublingual nitroglycerin (solid bars) did not differ between patients 
treated with rt-PA and those treated with placebo with p = 0.36 for 
the improvement in global and p = 0.17 for the improvement in 
regional ejection fraction, respectively. 
3, was determined at 17 2 0.8 h in the 47 patients initially 
admitted to a core hospital with catheterization facilities. 
Among the 24 patients treated with placebo undergoing early 
coronary angiography, 7 (29%) had TIMI grade 2 or 3 
perfusion of the infarct-related artery compared with I8 
(78%) of the 23 patients treated with rt-PA (p = 0.001). When 
the 7 placebo-treated and 18 rt-PA-treated patients with 
patent vessels were restudied on day 9, reocclusion was 
documented in 2 placebo-treated and 2 rt-PA-treated pa- 
tients. In the 59 patients who were initially admitted to a 
hospital without catheterization facilities and therefore un- 
derwent catheterization only on day 9, 15 (56%) of 27 
infarct-related vessels were patent in the placebo group and 
24 (75%) of 32 in the rt-PA group. This difference is not 
statistically significant (p = 0.14). 
Cardiac enzymes (Table 3). The time from symptom 
onset to peak MB CK activity was 12.9 ? 0.6 h in the rt-PA- 
treated patients and 17.9 + 0.6 h in the placebo-treated 
patients (p < 0.001). There was no difference between the 
Table 3. Creatine Kinase (CK) Data 
Placebo 





Time to peak MB CK (h) 17.9 ? 0.6 12.9 2 0.6 <O.ool 
(n = 55) (n = 57) 
Maximal MB CK (IU%ter) 43.0 ‘- 4.0 45.4 k 3.4 =0.66 
(n = 56) (n = 59) 
Area under the MB CK curve 911.9 ? 85.7 861.1 2 62.3 =0.63 
(W/liter) (n = 55) (n = 57) 
rt-PA r recombinant tissue-type plasminogen activator 
Global Regional 
Figure 2. Results of quantitative tomographic thallium scintigra- 
phy. Trends toward smaller global and regional irreversible thallium 
defects (hatched bars) among patients treated with tissue-type 
plasminogen activator (&PA) do not achieve statistical significance. 
Reversible thallium defects (open bars), both global and regional, did 
not differ between placebo and rt-PA groups. Measurements are 
expressed as mean values k SE. 
two groups in the maximal MB CK or in the area under the 
MB CK time-activity curves. 
Thallium scintigraphy (Fig. 2). Although there was a 
trend toward smaller irreversible and larger reversible de- 
fects in both global and regional estimates for rt-PA-treated 
patients, these differences did not achieve statistical signifi- 
cance. Similarly, the ratio of reversible to irreversible defect 
size did not differ significantly between rt-PA- and placebo- 
treated patients. 
Clinical outcome. Twenty patients underwent either cor- 
onary angioplasty or bypass surgery in the hospital, 5 who 
had received placebo and 15 who had received rt-PA (p = 
0.014). Two of the 20 required emergency repair of a 
ventricular septal defect (1 with concomitant coronary by- 
pass surgery); both subsequently died in the hospital and 
both had received rt-PA therapy. Six patients required 
urgent coronary angioplasty before day 9 because of recur- 
rent ischemia as defined by protocol; three had received 
placebo and three had received rt-PA. Twelve patients 
underwent revascularization in the hospital on or after day 9 
(coronary angioplasty in nine and bypass surgery in three). 
Four additional patients underwent revascularization be- 
tween hospital discharge and day 90; two of these had 
received placebo and two had received rt-PA. Reinfarction 
occurred in three placebo-treated and three rt-PA-treated 
patients. 
Eight patients, including five from the placebo group, 
died in the hospital. Two additional deaths occurred in the 
placebo group after hospital discharge and before day 90. 
Thus, the 90-day mortality rate was 12.5% for placebo- 
treated patients and 5.1% for rt-PA-treated patients (p = 
0.15). 
Side effects. Few serious adverse effects were observed 
in this study. Although superficial bleeding and oozing from 
puncture sites was common, only four patients, including 
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three from the placebo group, required transfusions because 
of a decrease in hemoglobin level to ~10 g/100 ml. There 
were no instances of cerebral hemorrhage and no other 
unexpected adverse effects in this study. 
Discussion 
This study demonstrates that recombinant tissue plasmi- 
nogen activator (r&PA) administered early after presentation 
with acute myocardial infarction results in improvement in 
both global and regional left ventricular function 9 days after 
hospital admission. We used double-chain tissue plasmino- 
gen activator (Burroughs Wellcome Co.) in this study, which 
is a purified rt-PA produced from large scale cultures of a 
well characterized mammalian cell line that contains the 
gene for human tissue plasminogen activator isolated from 
Bowes melanoma cells. Results from biologic activity assays 
show no discernible difference in biologic activity between 
Burroughs Wellcome rt-PA and Bowes melanoma t-PA. The 
strategy of dosing on a per weight basis in this study was 
derived from preliminary studies (5) in which this approach 
was found to achieve effective reperfusion and minimize 
bleeding complications. The maintenance infusion of rt-PA 
was changed part way through the trial because of a policy 
decision related to data that were acquired independent of 
the trial; these data (6) indicated a lack of benefit of longer 
infusions of rt-PA on the incidence of reocclusion and an 
increased incidence of bleeding complications associated 
with total dose and duration of infusion of rt-PA. 
These are the first human data attesting to the functional 
efficacy of this rt-PA preparation. In contrast to previous 
studies of the effects of rt-PA on left ventricular function, in 
which measurements of regional function were either un- 
available or failed to show a treatment effect, our study 
provides evidence that the improvement in global function is 
mediated through enhanced contraction in the infarct zone. 
The validity of the quantitative computer-based regional 
ejection fraction measurements in this study is substantiated 
by the independent visual wall motion analysis. 
Comparison with previous studies. It is of interest to 
compare this study with two previous randomized trials of 
rt-PA in myocardial infarction (8,9) that reported left ven- 
tricular function measurements both within the first 24 h 
after admission and later during the hospital convalescence. 
Although Guerci et al. (8) demonstrated a beneficial effect of 
rt-PA on left ventricular function on day 10, the magnitude of 
this effect may have been exaggerated by a corresponding 
decline in left ventricular function in their placebo group. In 
contrast, our study showed a trend to improved left ventric- 
ular function between early and late hospital assessments in 
placebo-treated patients that was consistent with previous 
natural history studies of left ventricular function after 
myocardial infarction (10,ll). The placebo-treated patients 
in the study of Guerci et al. (8) received concomitant medical 
therapy, including intravenous nitroglycerin for 48 h and 
calcium channel blockers throughout the hospital course. 
Moreover, initiation of heparin therapy was delayed 1 to 6 h 
after completion of study drug administration until cardiac 
catheterization was performed in all patients and a subset 
was submitted to early angioplasty. In view of the unfavor- 
able outcome of the placebo-treated patients in their trial and 
the ancillary treatments employed, it is difficult to assess the 
independent treatment effect of rt-PA. 
The Australian National Heart Foundation study (9) 
demonstrated a benefit of rt-PA on global left ventricular 
function assessed by single plane contrast ventriculography 
5 to 7 days after infarction. Despite this improvement in 
global function, a parallel improvement in regional function 
was not demonstrated and the benefit of rt-PA therapy could 
not be confirmed by radionuclide ventriculography at any 
time during the 90 day follow-up period. These findings 
notwithstanding, there was a suggestion of a treatment effect 
in patients with anterior infarction as early as day 2. Exam- 
ination of our own early functional data shows a similar 
trend to improved early function in the rt-PA group, as 
suggested by Top01 et al. (12). However, our study was not 
designed to address this question and we cannot exclude that 
this finding is influenced by differences in baseline variables. 
Timing of assessment of left ventricular function. The 
optimal time for assessment of the impact of thrombolytic 
therapy on left ventricular function is unclear. A review of 
reperfusion studies with functional outcomes highlights sub- 
stantial differences in the agents employed, as well as in the 
measurement techniques for functional assessment and their 
time of application. The improvement in global ejection 
fraction 9 days after treatment that was seen in our study 
was similar in magnitude to that observed by O’Rourke et al. 
(13). They used radionuclide ventriculography to study 
patients with a first myocardial infarction who presented 
within 2.5 h of initial chest pain; they assessed the effects of 
rt-PA 21 days after infarction to minimize the possible 
influence of myocardial stunning. The failure of nitroglycerin 
in our study to significantly enhance the beneficial effects of 
rt-PA on global and regional left ventricular function pro- 
vides further evidence that significant myocardial stunning 
may not be as important as previously believed, even at this 
relatively early phase in the convalescence of acute myocar- 
dial infarction. Alternatively, early rt-PA administration 
with commensurate rapid and effective reperfusion may 
minimize myocardial stunning. 
The high early patency rate in the rt-PA-treated patients 
in our study attests to the thrombolytic efficacy of this form 
of rt-PA and is consistent with previous findings. The low 
rate of reinfarction in this study, as well as the low rate of 
documented reocclusion in the subset of patients with early 
catheterization in whom it was specifically sought, is in 
contrast to earlier data and may reflect our rt-PA dosing 
strategy or the combined effects of rt-PA, heparin and 
JACC Vol. 13, No. 7 ARMSTRONG ET AL. 
June 1989: 1469-76 RANDOMIZED TRIAL OF RT-PA 
1475 
aspirin (14). The increase in patency between the early and 
the late study in the placebo group may account for the lack 
of a significant difference in late patency between the rt-PA 
and placebo groups. The mechanism and physiologic signif- 
icance of the improved late patency in the placebo-treated 
patients (who received heparin) remains unclear and worthy 
of further investigation. 
Creatine kinase MB isoenzyme activity peaked much 
earlier in the rt-PA group than in the placebo group and 
when taken in conjunction with the demonstrated high early 
rate of patency of the infarct-related coronary artery in a 
subset of these patients, it suggests successful early reper- 
fusion. The similarity of area under the MB CK time-activity 
curve in the placebo and rt-PA groups, coupled with the 
improvement in left ventricular function afforded by rt-PA, 
suggests that the enzyme data of the rt-PA group were 
influenced by washout (1.5). The actual infarct size was likely 
reduced compared with that in the placebo group. 
The reasons *for failure to demonstrate limitation of 
infarct size by thallium scintigraphy are unclear in light of 
the evidence of a favorable treatment effect afforded by both 
the functional and the enzymatic results. This result may 
reflect the insensitivity of this technique for detecting myo- 
cardial salvage, particularly with a relatively modest sample 
size. Alternatively, alteration of thallium kinetics in the 
acute phase of myocardial infarction may have confounded 
the ability to detect differences between infarcted and isch- 
emit myocardium. Ritchie et al. (16) reported irreversible 
tomographic thallium defect sizes comparable with those 
noted herein and they were also unable to demonstrate a 
favorable impact of reperfusion therapy with intracoronary 
streptokinase. 
Revascularization after thrombolysis. At the time our 
study began, there was genuine concern about the increased 
risk of recurrent ischemia, reocclusion and reinfarction in 
rt-PA-treated patients. The incidence of reocclusion and 
reinfarction during hospitalization was low in both the 
placebo and the rt-PA groups. Although urgent revascular- 
ization for recurrent ischemia was infrequently required 
before day 9, revascularization during hospitalization was 
undertaken more frequently in patients treated with t-t-PA 
than in those receiving placebo even though their attending 
physicians remained unaware of treatment assignment 
throughout the study. The policy of restricting revascular- 
ization to clinical need did not reduce the beneficial effect of 
reperfusion therapy on left ventricular function or on patient 
outcome. This finding is consistent with recent studies 
(17,18) of the acute effects of angioplasty as an adjunct to 
thrombolytic therapy in myocardial infarction, which show 
either no benefit or deleterious effects on both clinical 
outcome and left ventricular function. The mortality rate in 
our study was low and there was a tendency for it to be lower 
in the t-t-PA group; however, our trial was not designed to 
address this issue. 
Unlike other studies, our study employed a dosing by 
weight strategy that was associated with a low risk of 
bleeding. The clearly demonstrable beneficial effect of r&PA 
on coronary patency and global and regional left ventricular 
function in conjunction with a conservative approach to 
mechanical revascularization suggests that this therapeutic 
approach has wide applicability and promise for patients 
with acute transmural myocardial infarction. 
Appendix* 
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Liu, MD. 
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Michael Morrison, RTNM. 
Angiographic Committee: Robert Chisholm, MD, Peter Gladstone, MD. 
Aminul Haq, MD, Carl White, MD, Robert Wilson, MD. 
Angiographic Core Laboratory: Carl White. MD and Robert Wilson, MD, 
University of Minnesota, Minneapolis. 
ECG Committee: Paul Dorian, MD. Luigi Casella. MD. Louise Harris, 
MD. 
Safety Monitoring Board: John Cairns, MD, McMaster University, Ham- 
ilton, Ontario; Richard Ogilvie, MD, Wayne Taylor, MA, McMaster Univer- 
sity. Hamilton, Ontario. 
Enzyme Core Laboratory: St. Michael’s Hospital: Robert Patten, MD. 
Pathology Committee: Jack Butany. MD, Avrum Gotlieb, MD, and 
Malcolm Silver, MD. 
Principal Investigators: Paul Armstrong, MD, St. Michael’s Hospital; Jack 
Colman. MD, Mount Sinai Hospital: Eric Goode, MD, Scarborough Cente- 
nary: Betty Ann Hrycyshyn, MD, Oshawa General Hospital; Martin Myers, 
MD, Sunnybrook Medical Centre; John Blakely, MD, York Central Hospital; 
Paul Daly, MD, Toronto Western Hospital: Aminul Haq. MD, Toronto 
General Hospital; Christopher Morgan, MD, Wellesley Hospital; and Sherryn 
Roth, MD. Scarborough General Hospital. 
Study Nurses: Christine Beck, RN, BA; Diane Black, RN; Mary Anne 
Christensen, RN: Billie Nigro-Purcell, RN, BScN; and Donna Paterson, RN. 
Study Secretary: St. Michael’s Hospital: Maureen McClenaghan. 
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